Pacira BioSciences (NASDAQ:PCRX) Rating Reiterated by HC Wainwright

Pacira BioSciences (NASDAQ:PCRX)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $57.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 163.16% from the company’s previous close.

A number of other research firms also recently weighed in on PCRX. Barclays decreased their price target on Pacira BioSciences from $40.00 to $38.00 and set an “overweight” rating for the company in a research note on Wednesday, May 8th. JPMorgan Chase & Co. started coverage on Pacira BioSciences in a research report on Thursday, March 7th. They issued an “overweight” rating and a $45.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $43.00 price objective on shares of Pacira BioSciences in a research report on Tuesday. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, Pacira BioSciences presently has an average rating of “Moderate Buy” and a consensus price target of $46.10.

Pacira BioSciences Stock Down 4.7 %

PCRX stock opened at $21.66 on Tuesday. The company has a quick ratio of 4.78, a current ratio of 5.81 and a debt-to-equity ratio of 0.57. The business has a 50 day moving average price of $28.60 and a two-hundred day moving average price of $29.73. The company has a market cap of $1.01 billion, a price-to-earnings ratio of 15.15 and a beta of 0.88. Pacira BioSciences has a twelve month low of $20.52 and a twelve month high of $40.16.

Pacira BioSciences (NASDAQ:PCRX) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.04). The company had revenue of $167.12 million during the quarter, compared to the consensus estimate of $165.43 million. Pacira BioSciences had a net margin of 10.34% and a return on equity of 12.98%. Analysts anticipate that Pacira BioSciences will post 2.13 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Lauren Riker sold 3,970 shares of Pacira BioSciences stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $28.72, for a total transaction of $114,018.40. Following the completion of the sale, the senior vice president now directly owns 38,075 shares of the company’s stock, valued at approximately $1,093,514. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, SVP Lauren Riker sold 3,970 shares of Pacira BioSciences stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $28.72, for a total transaction of $114,018.40. Following the completion of the sale, the senior vice president now directly owns 38,075 shares of the company’s stock, valued at approximately $1,093,514. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Daryl Gaugler sold 1,000 shares of the company’s stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $28.38, for a total value of $28,380.00. Following the sale, the chief operating officer now owns 116,040 shares of the company’s stock, valued at $3,293,215.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 21,150 shares of company stock valued at $602,170. Insiders own 6.40% of the company’s stock.

Institutional Trading of Pacira BioSciences

A number of institutional investors have recently modified their holdings of PCRX. ICA Group Wealth Management LLC bought a new stake in shares of Pacira BioSciences during the 4th quarter valued at $30,000. GAMMA Investing LLC lifted its position in shares of Pacira BioSciences by 229.6% during the 2nd quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock valued at $38,000 after acquiring an additional 932 shares during the period. Park Place Capital Corp bought a new stake in shares of Pacira BioSciences during the 2nd quarter valued at $46,000. Quadrant Capital Group LLC lifted its position in shares of Pacira BioSciences by 61.5% during the 4th quarter. Quadrant Capital Group LLC now owns 2,324 shares of the company’s stock valued at $78,000 after acquiring an additional 885 shares during the period. Finally, Natixis acquired a new position in shares of Pacira BioSciences during the 1st quarter worth $95,000. 99.73% of the stock is currently owned by institutional investors.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.